安罗替尼治疗晚期非小细胞肺癌的临床效果

Abstract
Figure/Table
References (20)
Related Citation (10)

Download: PDF (534 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the efficacy and adverse effect of Anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 40 patients with advanced NSCLC (after second-line or further treatment) admitted to the Department of Oncology and Respiration of Xuzhou Central Hospital from May to October 2018 were admitted. They were randomly divided into observation group and control group according to the random number table method, with 20 cases in each group. The observation group was treated with Anlotinib (12 mg/d, 2 weeks on-treatment followed by 1 week off-treatment in a 21-day cycle), while the control group was treated with best supportive care. Objective response rate, disease control rate, progression free survival, overall survival and adverse effect were observed. Results There was no statistically significant difference in objective response rate between two groups (P ＞ 0.05). The disease control rate in the observation group was significantly higher than that in the control group (P ＜ 0.05). The progression free survival and overall survival in the observation group were significantly higher than those in the control group (P ＜ 0.05), grade 1-2 adverse effects were common in the observation group, grade 3-4 adverse effects were mainly associated with hand-foot syndrome, oral mucositis, poor appetite and fatigue. Conclusion Anlotinib is effective in the treatment of advanced NSCLC, and the adverse effects were tolerable.

Key words： Anlotinib Lung neoplasms Advanced lung cancer Targeted therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DAI Xiumei1 ZHANG Youwei1 HAN Liang1 LIU Yanhua1 LI Ruoran2

Cite this article:

DAI Xiumei1 ZHANG Youwei1 HAN Liang1 LIU Yanhua1 LI Ruoran2. Clinical efficacy of Anlotinib in the treatment of advanced non-small cell lung cancer[J]. 中国医药导报, 2019, 16(32): 95-98.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I32/95

[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Kaneda T，Yoshioka H，Tamiya M，et al. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer [J]. BMC Cancer，2018，18（1）：6-13.
[3] Xu H，Xu F，Zhu W，et al. Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer [J]. Thorac Cancer，2018，9（8）：1005-1011.
[4] Hall RD，Le TM，Haggstrom DE，et al. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer （NSCLC） [J]. Transl Lung Cancer Res，2015，4（5）：515-523.
[5] Liu Z，Wang J，Meng Z，et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer：Analysis on ALTER-0303 study [J]. Cancer Med，2018，7（7）：3011-3021.
[6] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline （version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247.
[7] Trotti A，Colevas AD，Setser A，et al. CTCAE v3.0： development of a comprehensive grading system for the adverse effects of cancer treatment [J]. Semin Radiat Oncol，2003， 13（3）：176-181.
[8] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[9] Chan BA，BG H. Targeted therapy for non-small cell lung cancer：current standards and the promise of the future [J]. Transl Lung Cancer Res，2015，4（1）：36-54.
[10] Zhang Q，Qin N，Wang J，et al. Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma [J]. Thorac Cancer，2016，7（1）：3-8.
[11] Wang J，Chen J，Guo Y，et al. Strategies targeting angiogenesis in advanced non-small cell lung cancer [J]. Oncotarget， 2017，8（32）：53854-53872.
[12] Si X，Li Z，Wang H，et al. Quality of life results from a randomized，double-blinded，placebo-controlled，multi-center phase Ⅲ trial of anlotinib in patients with advanced non-small cell lung cancer [J]. Lung Cancer，2018，122：32-37.
[13] Sun Y，Niu W，Du F，et al. Safety，pharmacokinetics，and antitumor properties of anlotinib，an oral multi-target tyrosine kinase inhibitor，in patients with advanced refractory solid tumors [J]. J Hematol Oncol，2016，9（1）：105.
[14] Han B，Li K，Wang Q，et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer [J]. JAMA Oncol，2018，4（11）：1569-1575.
[15] Shen G，Zheng F，Ren D，et al. Anlotinib：a novel multi-targeting tyrosine kinase inhibitor in clinical development [J]. J Hematol Oncol，2018，11（1）：120.
[16] 程颖，吴一龙，陆舜，等.中国临床肿瘤学会（CSCO）原发性肺癌诊疗指南（2018.V1）[M].北京：人民卫生出版社，2018：16-22.
[17] 斯晓燕，王汉萍，张晓彤，等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志，2018，57（11）：830-834.
[18] Shi J，Han B，Li K，et al. Subgroup analysis of elderly patients（pts）in ALTER0303：Anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized，double-blind，placebo-controlled phase Ⅲ ALTER0303 trial [J/OL]. J Clin Oncol，2018，36（15_suppl）：e21181. doi：10.1200/JCO.2018.36.15_suppl.e21181.
[19] Cheng Y，Han B，Li K，et al. Subgroup analysis of histology in ALTER0303：Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients（pts）[J/OL]. J Clin Oncol，2018，36（15_suppl）：9080.
[20] Si X，Zhang L，Wang H，et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer：Experiences in ALTER-0303 [J]. Thorac Cancer，2019，10（3）：551-556.